2-Amino-4,7-dihydro-5-[2-[4-(methoxycarbonyl)phenyl]ethyl]-4-oxo-3H-pyrrolo[2,3-d]pyrimidine

We are 2-Amino-4,7-dihydro-5-[2-[4-(methoxycarbonyl)phenyl]ethyl]-4-oxo-3H-pyrrolo[2,3-d]pyrimidine CAS:155405-80-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 2-Amino-4,7-dihydro-5-[2-[4-(methoxycarbonyl)phenyl]ethyl]-4-oxo-3H-pyrrolo[2,3-d]pyrimidine
CAS.NO: 155405-80-4
Synonyms:
methyl 4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoate
Methyl 4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoate
Methyl 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoate
4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic Acid Methyl Ester

Molecular Formula:C16H16N4O3
Molecular Weight:312.32300

Physical and Chemical Properties:
Density: 1.44 g / cm3
Boiling point: 562.3ºC at 760 mmHg
Melting point:/
Flash point: 293.9ºC
Refractive index: 1.691

Specification:
Appearance:white to pale yellow solid
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Pemetrexed disodium CAS:150399-23-8

Related News: International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.3-Fluoro-4-morpholinoaniline Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API.3-cloroanilina CAS:108-42-9 We partner with life science companies of all sizes, drawing on over 20 years of industry experience.6-azido-2-fluoro-7H-purina CAS:143482-58-0 We partner with life science companies of all sizes, drawing on over 20 years of industry experience.An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D.